Pharma Bribes

WASHINGTON — Boston-based Alexion Pharmaceuticals agreed Thursday to pay $21.5 million to settle SEC charges of bribing officials in Turkey and Russia to get favorable treatment for its primary drug, Soliris, which treats a blood disease.